Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
NCT03345940 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · PHASE4 · terminated · last registry update 2019-10-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor” | – | Registry record, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-14Results posted on the registry: Celgene, Ozanimod + Placebo (NCT01647516)
- 2020-10-08Results posted on the registry: Celgene, RPC1063 (NCT02531113)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
- 2020-07-21Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT03257358)
- 2020-04-20Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab (NCT04353492)
- 2020-03-02Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT01705236)
- 2019-11-25Phase 3 first posted: Everstar Therapeutics Limited, Etrasimod + Placebo (NCT04176588)
- 2019-11-21Phase 3 first posted: Pfizer, Etrasimod + Etrasimod (NCT04173273)
- 2019-11-07Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT01201356)
- 2019-10-25Phase 3 first posted: Celgene, RPC-1063 (NCT04140305)
- 2019-09-30Results posted on the registry: Novartis Pharmaceuticals, Fingolimod 0.5 mg (NCT02373098)
- 2019-09-23Results posted on the registry: Novartis Pharmaceuticals, FTY720 (NCT01585298)
- 2019-06-24Phase 3 first posted: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03996369)
- 2019-05-28Results posted on the registry: Novartis Pharmaceuticals, fingolimod + glatiramer acetate (NCT01633112)
- 2019-05-28Also stopped (terminated): Novartis Pharmaceuticals, fingolimod + glatiramer acetate (NCT01633112)
- 2019-05-15Phase 3 first posted: Pfizer, Etrasimod (NCT03950232)
- 2019-05-14Results posted on the registry: Isfahan University of Medical Sciences, Fingolimod + Placebo (for Fish Oil) (NCT02939079)
- 2019-05-10Phase 3 first posted: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03945188)
- 2019-04-16Phase 3 first posted: Celgene, Ozanimod (NCT03915769)
- 2019-04-16Results posted on the registry: Indiana University, Fingolimod + placebo (NCT01779700)
- 2019-02-27Results posted on the registry: Novartis Pharmaceuticals, 0,5 mg Fingolimod (NCT02575365)
- 2019-02-27Also stopped (terminated): Novartis Pharmaceuticals, 0,5 mg Fingolimod (NCT02575365)
- 2019-02-08Results posted on the registry: Novartis Pharmaceuticals, fingolimod (NCT02720107)
- 2019-01-25Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (FTY720) (NCT01498887)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision